Department of Otolaryngology-Head and Neck Surgery, Affiliated Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, 200031, China.
Department of Otolaryngology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Cancer Lett. 2021 Feb 28;499:301-313. doi: 10.1016/j.canlet.2020.11.001. Epub 2020 Nov 4.
Circular RNAs (circRNAs) act as competing endogenous RNAs, which are involved in the regulation of many types of cancers. They primarily function by sponging microRNAs (miRNAs) and influencing the expression of miRNA by target messenger RNA. However, the role of circRNAs in the progression of nasopharyngeal carcinoma (NPC) remains largely unclear. In this study, differentially expressed miRNAs associated with NPC were screened using microarray analyses, from which miR-107 was identified. Increased miR-107 expression was associated with poor prognosis in NPC, and miR-107 promoted the proliferation and migration of NPC cells. TGFBR2 was identified as the direct target of miR-107, which could reverse its effect on NPC cells. Furthermore, the expression of circTGFBR2 was downregulated in NPC tissue samples, while circTGFBR2 overexpression correlated with favorable prognosis in NPC. Functionally, circTGFBR2 overexpression inhibited the proliferation and migration of NPC cells both in vitro and in vivo. Further analysis showed that circTGFBR2 sponged miR-107, leading to the upregulation of TGFBR2 expression and suppression of NPC progression. Therefore, circTGFBR2 may serve as a novel tumor suppressive factor and potential target for new therapies in NPC patients.
环状 RNA(circRNAs)作为竞争性内源 RNA,参与多种类型癌症的调控。它们主要通过海绵 microRNA(miRNAs)并影响 miRNA 对靶信使 RNA 的表达来发挥作用。然而,circRNAs 在鼻咽癌(NPC)进展中的作用在很大程度上尚不清楚。在这项研究中,通过微阵列分析筛选出与 NPC 相关的差异表达 miRNA,从中鉴定出 miR-107。miR-107 表达增加与 NPC 的不良预后相关,并且 miR-107 促进 NPC 细胞的增殖和迁移。TGFBR2 被鉴定为 miR-107 的直接靶标,它可以逆转其对 NPC 细胞的作用。此外,circTGFBR2 在 NPC 组织样本中的表达下调,而 circTGFBR2 的过表达与 NPC 中的良好预后相关。功能上,circTGFBR2 的过表达在体外和体内均抑制 NPC 细胞的增殖和迁移。进一步分析表明,circTGFBR2 吸附 miR-107,导致 TGFBR2 表达上调并抑制 NPC 进展。因此,circTGFBR2 可能作为一种新的肿瘤抑制因子,并为 NPC 患者的新疗法提供潜在的靶点。
Eur Rev Med Pharmacol Sci. 2019-12
Eur Rev Med Pharmacol Sci. 2019-1
Cell Death Discov. 2024-4-25
Int J Gen Med. 2023-5-25
Noncoding RNA Res. 2023-3-21